

Supplementary Online Content

Liu F, Huang C, Xu Z, et al; for the Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage I gastric cancer: the CLASS02 multicenter randomized clinical trial. *JAMA Oncol*. Published online August 20, 2020. doi:10.1001/jamaoncol.2020.3152

eTable 1. Eligibility Criteria

eTable 2. Clinical Characteristics at Baseline

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Eligibility Criteria
Inclusion
Aged 18-75 years
Primary lesion is pathologically diagnosed as gastric adenocarcinoma
Clinical stage IA (T1N0M0) or IB (T1N1M0, T2N0M0) according to AJCC-7th TNM staging system
Tumor located in the upper or middle third of the stomach
No invasion to Z-line
Curative resection is expected to be achievable by total gastrectomy with D1+/D2 lymphadenectomy
BMI < 30 kg/m ²
ECOG PS 0 or 1
ASA class: I, II, or III
Sufficient organ functions
Written informed consent
Exclusion
Preoperative examination indicate enlargement of perigastric or retroperitoneal lymph nodes(≥1.0cm)
Preoperative neoadjuvant chemotherapy or radiotherapy
Previous history of upper abdominal surgery (except for laparoscopic cholecystectomy)
Women during pregnancy or breast-feeding
Synchronous or metachronous (within 5 years) malignancies
Body temperature ≥ 38°C before surgery or infectious disease with a systemic therapy indicated
Severe mental disease
Severe respiratory disease
Severe hepatic and renal dysfunction
Unstable angina pectoris or history of myocardial infarction within 6 months
History of cerebral infarction or cerebral hemorrhage within 6 months
Continuous systemic steroid therapy within 1 month (except for topical use)
Gastric cancer complications (bleeding, perforation, obstruction) that requiring emergency surgery
Patients are participating or have participated in another clinical trial (within 6 months)
Abbreviation: AJCC, American Joint Committee on Cancer; TNM, Tumor-Node-Metastasis; BMI, Body Mass Index; ECOG PS, Eastern Cooperative Oncology Group performance status; ASA, American Society of Anesthesiologists.

eTable 2. Clinical Characteristics at Baseline					
Factor		Laparoscopic Surgery		Open Surgery	
All patients- No. (%)		105 (100)		109 (100)	
Age (years)- mean (SD)		59.80 (9.42)		59.39 (9.16)	
Gender- No. (%)					
Female		30 (28.57)		29 (26.61)	
Male		75 (71.43)		80 (73.39)	
BMI (Kg/m ²)- mean (SD)		23.87 (3.07)		23.71 (3.13)	
ECOG PS- No. (%)					
0		62 (59.05)		71 (65.14)	
1		41 (39.05)		36 (33.03)	
Missing data		2 (1.90)		2 (1.83)	
Comorbidity- No. (%)					
None		62 (59.05)		54 (49.54)	
One or more		43 (40.95)		55 (50.46)	
ASA class					
I		52 (49.52)		56 (51.38)	
II		52 (49.52)		47 (43.12)	
III		1 (0.95)		6 (5.50)	
Tumor size (cm)- mean (SD)		2.79 (3.18)		2.40 (2.15)	
EGJA- No. (%)					
No		51 (48.57)		64 (58.72)	
Yes		54 (51.43)		44 (40.37)	
Missing data		0 (0.00)		1 (0.92)	
Prior EMR/ESD					
No		95 (90.48)		101 (92.66)	
Yes		10 (9.52)		8 (7.34)	
Differentiation- No. (%)					
Well		17 (16.19)		17 (15.60)	
Moderate		39 (37.14)		42 (38.53)	
Poorly		34 (32.38)		38 (34.86)	
Undifferentiated		5 (4.76)		1 (0.92)	
Unable to evaluate		10 (9.52)		7 (6.42)	
Missing data		0 (0.00)		4 (3.67)	
Pathologic T stage- No. (%)					
T0		1 (0.95)		0 (0.00)	
Tis		2 (1.90)		4 (3.67)	
M		35 (33.33)		30 (27.52)	
SM		35 (33.33)		44 (40.37)	
MP		19 (18.10)		20 (18.35)	
SS		10 (9.52)		9 (8.26)	
SE		3 (2.86)		2 (1.83)	
Pathologic N stage - No. (%)					

N0		85 (80.95)		95 (87.16)	
N1		11 (10.48)		6 (5.50)	
N2		4 (3.81)		4 (3.67)	
N3a		5 (4.76)		1 (0.92)	
N3b		0 (0.00)		3 (2.75)	
Pathologic M stage - No. (%)					
No		105 (100)		109 (100)	
Yes		0 (0.00)		0 (0.00)	
Pathologic TNM stage- No. (%)					
0		3 (2.86)		4 (3.67)	
IA		66 (62.86)		74 (67.89)	
IB		16 (15.24)		13 (11.93)	
IIA		8 (7.62)		8 (7.34)	
IIB		5 (4.76)		6 (5.50)	
IIIA		3 (2.86)		1 (0.92)	
IIIB		3 (2.86)		1 (0.92)	
IIIC		1 (0.95)		2 (1.83)	
IV		0 (0.00)		0 (0.00)	
Abbreviation: SD, standard deviation; BMI, Body Mass Index; ECOG PS, Eastern Cooperative Oncology Group performance status; ASA, American Society of Anesthesiologists; EGJA, esophagogastric junctional adenocarcinoma; EMR, Endoscopic Mucosal Resection; ESD, Endoscopic Submucosal Dissection; TNM, Tumor-Node-Metastasis.					